Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation

Zondlo, Susan Carr; Wang, Xinkang; Feuerstein, Giora

doi:10.1016/s0049-3848(02)00090-7

Cited by 3 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to both our findings and those of NannizziAlaimo et al (27) with intravenous GP IIb/IIIa antagonists, Zondlo et al (31) reported that oral GP IIb/IIIa antagonists (roxifiban and orbofiban) in pharmacologically relevant doses do not affect the release of sCD40L from platelets in vitro. The resultant lack of inhibition of the proinflammatory (15)(16)(17)(18) and prothrombotic effects (8) of sCD40L may contribute to the reported lack of clinical effectiveness of oral GP IIb/IIIa antagonists (32).…”

Section: Discussioncontrasting

confidence: 99%

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Furman

Krueger

Linden

et al. 2004

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 99%

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Furman

Krueger

Linden

et al. 2004

Journal of the American College of Cardiology

119

View full text Add to dashboard Cite

show abstract

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease

Azar

Kassab

Zoghbi

et al. 2006

American Heart Journal

View full text Add to dashboard Cite

Platelets as a Novel Target for PPAR?? Ligands

et al. 2006

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor gamma (PPARgamma) is an important transcription factor for lipid and glucose metabolism. Currently, the PPARgamma ligands rosiglitazone and pioglitazone are used for the treatment of type 2 diabetes mellitus because they are potent insulin sensitizers. Recently, PPARgamma has emerged as an important anti-inflammatory factor. Platelets, anucleate cells involved in hemostasis, have also been implicated as key contributors to inflammation, because they produce many pro-inflammatory and pro-atherogenic mediators when activated. Surprisingly, it was discovered recently that platelets contain PPARgamma and that PPARgamma ligands, both natural and synthetic, inhibit platelet activation and release of bioactive mediators. In particular, release of soluble CD40 ligand (sCD40L) and thromboxane (TXA(2)) was inhibited by PPARgamma ligands in thrombin-activated platelets. CD40L signaling induces pro-inflammatory processes in many cell types, and increased blood levels of sCD40L are closely associated with inflammation, diabetes, and cardiovascular disease. Targeting platelet PPARgamma will, therefore, be an important treatment strategy for the attenuation of chronic inflammatory processes and prevention of thrombus formation.

show abstract

Effects of orally active glycoprotein IIb/IIIa antagonists on platelet CD40 ligand (CD154) expression and platelet-heteroaggregate formation

Cited by 3 publications

References 16 publications

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease

Platelets as a Novel Target for PPAR?? Ligands

Contact Info

Product

Resources

About